Chris Hoyt, CEO, and Charbel Moussa, MBBA, PhD, Director of Scientific Advisory Board and co-founder of KeifeRx, an emerging clinical-stage biopharmaceutical company, discuss the development of novel and optimized, low-dose, orally delivered tyrosine kinase inhibitors (TKIs) to treat neurodegenerative and immune diseases. The indications of focus are Alzheimer’s disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, MCAS, and Lyme Disease. The Company’s lead and most advanced clinical candidate (Phase III ready) is KFRX01 (Nilotinib BE), an optimized reformulation with improved bioavailability and solubility under development for the treatment of early Alzheimer’s disease. 

Chris is an entrepreneurial executive with experience starting, funding and operating venture-backed companies across a number of industries including software, health care and technology services. Most recently, Chris was the Co-Founder and CFO of Upskill, Inc., an enterprise software platform for enterprise use of wearable technology. Upskill raised over $65 million in venture capital and recently sold to TeamViewer AG. Chris has raised over $400 million in debt and equity and has completed over two dozen acquisitions and divestitures totaling more than $2 billion. Chris has been active in the early-stage start-up ecosystem as a co-founder and board member at organizations including Yet Analytics, Digital Harbor Foundation, and BTS Software Solutions. Chris is a venture partner at Moonshoots Capital and has been an advisor for a number of other high-growth companies.

Liked it? Take a second to support healthprofessionalradio on Patreon!